At Aerami Therapeutics, we leverage our proprietary inhalation technology to develop differentiated inhaled therapies for the treatment of cardiopulmonary conditions.
A drug-device combination product candidate in Phase 1 for the treatment of pulmonary arterial hypertension
An inhaled glucagon-like peptide-1 (GLP-1) analog for the treatment of post-prandial hyperglycemia associated with Type 2 diabetes
A soft mist inhaled human insulin to improve glycemic control in Type 1 and Type 2 diabetes
Aerami Therapeutics is a clinical stage biopharmaceutical company engaged in the development of differentiated inhaled therapies for the treatment of cardiopulmonary conditions.
Sign up today and receive company updates straight to your inbox.